Arava

Indicated to manage rheumatoid arthritis to mitigate joint damage.

Strengths: 10 · 20mg

Medicine details

Therapeutic class

Disease-Modifying Antirheumatic Drug (DMARD)

Pharmacological class

Pyrimidine Synthesis Inhibitor

Minor side effects

diarrhoea; nausea; headache; alopecia

Moderate side effects

hypertension; elevated liver enzymes; weight loss; rash

Dosage forms

Film-coated tablet

Administration route

Oral use

Patient summary

Indicated to manage rheumatoid arthritis to mitigate joint damage.

Prescription status

POM

Manufacturer

Sanofi

Onset Time

4–8 weeks

Duration

long-term

Storage instructions

Store below 25°C in a dry place.

Drug interactions

hepatotoxic drugs; cholestyramine; activated charcoal

Age restrictions

Not recommended for those under 18 years.

Contraindications

pregnancy; severe hepatic impairment; severe immunodeficiency; hypersensitivity to leflunomide

Precautions and warnings

regular blood monitoring recommended; monitor liver function; avoid live vaccines during treatment

Serious side effects

severe liver injury — requires immediate medical attention; interstitial lung disease — requires immediate medical attention; severe haematological disorders — requires immediate medical attention

Mechanism of action

Inhibits dihydroorotate dehydrogenase, which reduces pyrimidine synthesis, thereby inhibiting the proliferation of activated T-lymphocytes.

Pregnancy and breastfeeding

Pregnancy: Absolute contraindication; must use strict contraception. Breastfeeding: Contraindicated.

Arava

Indicated to manage rheumatoid arthritis to mitigate joint damage.

Editorial Notes

  • Active ingredient(s): Leflunomide
  • Listed indication(s): Rheumatoid Arthritis, Psoriatic Arthritis

Usually available as

  • 60 tablets - 10 mg205-10-mg-2053
  • 60 tablets - 20 mg205-20-mg-2048